Newcastle upon Tyne Hospitals NHS Foundation Trust

Running trials

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

  NCT07227896· AbbVie· Source

• Recruiting

  Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

  NCT07443956· NHS Greater Glasgow and Clyde· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· Phase 3· AbbVie· Source

• Recruiting

  GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

  NCT07127172· Neuralink Corp· Source

• Recruiting

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

  NCT06735248· Phase 2· ModernaTX, Inc.· Source

• Recruiting

  Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

  NCT06830759· AbbVie· Source

• Recruiting

  Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  NCT06712355· Phase 3· BioNTech SE· Source

• Recruiting

  Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

  NCT06487273· Physio-Assist· Source

• Active, not recruiting

  A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

  NCT06812325· Phase 3· Viridian Therapeutics, Inc.· Source

• Recruiting

  Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease

  NCT06347536· Phase 3· Guy's and St Thomas' NHS Foundation Trust· Source

• Recruiting

  Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old

  NCT06769633· Phase 2· Italfarmaco· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Cerevance· Source

• Active, not recruiting

  A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT06508658· Phase 3· Genmab· Source

• Active, not recruiting

  Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

  NCT06449209· Phase 2· BioNTech SE· Source

• Active, not recruiting

  Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study

  NCT06149650· Cardiovascular and Interventional Radiological Society of Europe· Source

• Recruiting

  A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

  NCT06380816· Phase 1/2· Cancer Research UK· Source

• Recruiting

  Anti-viral Action Against Type 1 Diabetes Autoimmunity

  NCT06452654· Phase 4· Technical University of Munich· Source

• Recruiting

  Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

  NCT05933057· Phase 3· Italfarmaco· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06191744· Phase 3· Genmab· Source

• Recruiting

  A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies

  NCT05789758· Biogen· Source

• Recruiting

  Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

  NCT05848765· Phase 2· University of Birmingham· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

  NCT05347095· Phase 3· Janssen-Cilag Ltd.· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

  NCT05409066· Phase 3· Genmab· Source

• Active, not recruiting

  Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

  NCT05315258· Phase 2· University of Oxford· Source

• Recruiting

  Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

  NCT05142189· Phase 1· BioNTech SE· Source

• Recruiting

  Lifestyle Behaviours of Women Newly Diagnosed With Heart Failure

  NCT05416879· Newcastle University· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source

• Active, not recruiting

  Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

  NCT05059522· Phase 3· Pfizer· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

• Recruiting

  Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole

  NCT04965298· Phase 3· Norfolk and Norwich University Hospitals NHS Foundation Trust· Source

• Active, not recruiting

  The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)

  NCT04573881· HistoSonics, Inc.· Source

• Recruiting

  A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

  NCT04786262· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· Phase 3· Karyopharm Therapeutics Inc· Source

• Recruiting

  A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy

  NCT07856329· Phase 2/3· Genethon· Source

• Recruiting

  iCorMicA - Stratified Medicine in Angina

  NCT04674449· NHS Greater Glasgow and Clyde· Source

• Active, not recruiting

  UNICORNS: Uveitis in Childhood Prospective National Cohort Study

  NCT05385757· Institute of Child Health· Source

• Active, not recruiting

  Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

  NCT04524611· Phase 3· AbbVie· Source

• Active, not recruiting

  Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

  NCT04468984· Phase 3· AbbVie· Source

• Recruiting

  Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

  NCT04302870· Phase 2/3· University of Edinburgh· Source

• Active, not recruiting

  Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

  NCT04042025· Phase 3· Novartis Gene Therapies· Source

• Active, not recruiting

  Paediatric Sjögren Syndrome Cohort Study and Repository (PaedSSCoRe)

  NCT04762108· University College, London· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Recruiting

  ICONIC: Improving Outcomes Through Collaboration in OsteosarComa

  NCT04132895· University College, London· Source

• Active, not recruiting

  A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta

  NCT04253015· RECORDATI GROUP· Source

• Active, not recruiting

  LITMUS Imaging Study

  NCT05479721· University of Oxford· Source

Showing 50 of 65.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• ALS (motor neurone disease)2 recruiting
• Colorectal cancer2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Follicular lymphoma2 recruiting
• Head and neck cancer2 recruiting
• Macular degeneration2 recruiting
• Obesity2 recruiting
• Type 1 diabetes2 recruiting
• Type 2 diabetes2 recruiting
• Acute myeloid leukaemia1 recruiting
• Bronchiectasis1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Cystic fibrosis1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Mitochondrial disease1 recruiting
• Multiple sclerosis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Sarcoma1 recruiting
• Spinal cord injury1 recruiting
• Spinal muscular atrophy1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Terminated

  Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease

  NCT07313176· Britannia Pharmaceuticals Ltd.· Source

• Completed

  A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

  NCT06299111· Phase 2· Regeneron Pharmaceuticals· Source

• Completed

  An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06021054· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)

  NCT06126146· AbbVie· Source

• Completed

  Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)

  NCT05780151· Phase 4· Mira Zuidgeest· Source

• Completed

  A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

  NCT05218655· Phase 3· PTC Therapeutics· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Terminated

  An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

  NCT05267574· Phase 2/3· Reneo Pharma Ltd· Source

• Completed

  Immune Responses to COVID-19 Vaccination in Lymphoma Patients

  NCT04858568· University Hospital Southampton NHS Foundation Trust· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

  NCT04378075· Phase 2/3· PTC Therapeutics· Source

• Completed

  Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

  NCT03982394· AbbVie· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Completed

  Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.

  NCT03644303· Royal Marsden NHS Foundation Trust· Source

• Completed

  A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

  NCT03607422· Phase 3· AbbVie· Source

• Completed

  A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

  NCT03587116· Phase 3· Pfizer· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy

  NCT03032172· Phase 2· Hoffmann-La Roche· Source

• Completed

  Apixaban for the Acute Treatment of Venous Thromboembolism in Children

  NCT02464969· Phase 4· Bristol-Myers Squibb· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Mitochondrial disease18 works · 4 trials
• Head and neck cancer12 works · 3 trials
• Duchenne muscular dystrophy10 works · 3 trials
• Bronchiectasis9 works · 1 trial
• Spinal muscular atrophy9 works · 3 trials
• Giant cell arteritis6 works · 0 trials
• Primary biliary cholangitis4 works · 2 trials
• Testicular cancer4 works · 0 trials
• Myotonic dystrophy3 works · 0 trials